Loading organizations...
§ Private Profile · Espoo, Southern Finland, Finland
Medical device developer creating minimally invasive transcatheter mitral valve repair solutions for mitral regurgitation, using proprietary helix.
HVR Cardio, based in Espoo, Finland, develops transcatheter mitral valve repair (TMVR) solutions, including the investigational CathHelix device, utilizing proprietary helix technology to treat mitral regurgitation. Its minimally invasive CathHELIX Annuloplasty System is designed for safer, less traumatic cardiac interventions, and remains investigational globally. The company secured €10.7 million ($11.1M) in Series B financing in January 2023, led by Innovestor Life Science Fund and Tesi, and operates with an estimated 11-20 employees and a $3.2 million valuation. Its leadership team includes CEO Tom Fleming and CTO Tim Girton, both formerly of Boston Scientific. HVR Cardio was founded in 2009 by Olli Keränen. Its business model centers on venture-funded medical device developer, raised €10.7 million Series B financing in January 2023 led by Innovestor Life Science Fund and Tesi.
HVR Cardio has raised $11.1M across 1 funding round.
HVR Cardio has raised $11.1M in total across 1 funding round.
HVR Cardio has raised $11.1M in total across 1 funding round.
HVR Cardio's investors include Pekka Simula, Tesi.
HVR Cardio has raised $11.1M across 1 funding round. Most recently, it raised $11.1M Series B in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 12, 2023 | $11.1M Series B | Pekka Simula, Tesi | — | Announced |